Abbott Laboratories $ABT Shares Sold by DSM Capital Partners LLC

Key Points

• DSM Capital Partners LLC reduced its holdings in Abbott Laboratories by 0.6%, now owning 854,111 shares, valued at approximately $113.3 million.
• Abbott Laboratories recently announced a quarterly dividend of $0.59 per share, with a dividend yield of 1.8% and a payout ratio of 29.57%.
• Analysts are generally optimistic about Abbott's stock, with a consensus rating of "Moderate Buy" and an average price target of $144.47.

DSM Capital Partners LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 0.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 854,111 shares of the healthcare product maker's stock after selling 5,293 shares during the period. Abbott Laboratories comprises 2.0% of DSM Capital Partners LLC's investment portfolio, making the stock its 19th biggest position. DSM Capital Partners LLC's holdings in Abbott Laboratories were worth $113,298,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Three Seasons Wealth LLC purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $1,428,000. Kelly Financial Services LLC purchased a new position in Abbott Laboratories in the first quarter valued at $216,000. Voleon Capital Management LP acquired a new stake in Abbott Laboratories in the fourth quarter valued at $273,000. Bank Pictet & Cie Europe AG lifted its holdings in Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after buying an additional 2,774 shares during the last quarter. Finally, Edge Financial Advisors LLC increased its holdings in shares of Abbott Laboratories by 3.3% in the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after acquiring an additional 81 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $0.8560 during trading on Tuesday, hitting $131.1260. 1,676,219 shares of the company were exchanged, compared to its average volume of 6,845,192. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm's fifty day moving average price is $131.34 and its 200 day moving average price is $131.24. Abbott Laboratories has a 1 year low of $110.33 and a 1 year high of $141.23. The company has a market cap of $228.22 billion, a price-to-earnings ratio of 16.43, a PEG ratio of 2.50 and a beta of 0.70.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were paid a dividend of $0.59 per share. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ABT shares. Mizuho boosted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Wells Fargo & Company cut their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Morgan Stanley increased their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Raymond James Financial decreased their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday, July 18th. Finally, Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.